Hemab Therapeutics Holdings, In (COAG) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.82
- Surprise
- —
- Score today
- 5.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64 — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates COAG Sell at 5.8/10; no pre/post engine snapshot brackets this report.
1 of the last 1 quarters beat the estimate. Next scheduled report: 2026-11-16.
What argues against it
- Quality below floor (2.5 < 4.0)
- Momentum score 2.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $39.40
- Price target
- $53.24
- Stop
- $37.81
- Upside to target
- +35.1%
- Reward-to-risk
- 2.3:1
Risk check: RSI 25 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
COAG at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.84B
- P/E (fwd)
- -15.5
- 52-week range
- $23.00–$55.42
- Off 52-week high
- 28.9%
- RSI (14)
- 25
- Volume vs avg
- 1.19×
- Score today
- 5.8/10